Treatment goal
Prove immune-evasion technology works in a human, ahead of a therapeutic-dose product.
Type of approach
Gene-edited (hypoimmune), donor-derived islet cells — designed to evade immune attack without systemic immunosuppression.
Current evidence
Early human safety / proof-of-concept — Phase 1, peer-reviewed (NEJM) with a company-reported 14-month update.
Trial phase & enrollment
Phase 1. Single participant reported in this readout — a proof-of-concept cohort, not a powered efficacy trial.
Who may qualify
Not applicable to this specific proof-of-concept dose.Confirm current enrollment status for any related Sana study before treating this as an open trial.
Location & travel
Not applicable to this readout.Confirm current site(s) for any related Sana study before publishing travel detail.
What participants undergo
Infusion of gene-edited donor islet cells at a small, intentionally non-therapeutic dose; no immunosuppression regimen; ongoing C-peptide and safety monitoring.
Possible benefits
None claimed for this participant specifically — the dose was exploratory. The benefit is proof that the underlying immune-evasion approach can work in a human, informing the therapeutic-dose program.
Known & unknown risks
No immunosuppression-related risk, by design. Long-term durability and safety at a therapeutic dose remain unknown and untested.
Immunosuppression requirement
None — this is the headline finding.
Results so far
C-peptide (insulin production) detectable and continuing past 14 months in the one participant dosed.
Definition of success used
Sustained C-peptide production without immunosuppression — not insulin independence, which this dose was never designed to produce.
Duration / follow-up
14+ months and ongoing at last company update.
Cost & compensation
Not applicable / not disclosed for this readout.Standing caveat applies if a future therapeutic-dose trial opens enrollment.
Sponsor
Sana Biotechnology.
Do not confuse with
SC451, Sana's stem-cell-derived clinical candidate — 🧪 Not Yet Scored, Preclinical, no human data. UP421 and SC451 are different products; UP421's results never transfer to SC451.